OWCP Looks to Bring Pharma-Grade Cannabis Therapeutics to Market!!!
OWCP is conducting clinical trials of cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder and migraines.
Big Money to be made here.
Multiple myeloma - orphan status designation possible - $7.3 billion in 2014 to $8.9 billion by 2021 Psoriasis - marketing of a cannabinoid-based topical cream - $6.6 billion in 2014 to over $13.3 billion by 2024 Fibromyalgia - orphan status designation possible - $1.8 billion in 2013 to $1.9 billion by 2023 Post-Traumatic Stress Disorder ( PTSD ) - annual cost to society of anxiety disorders is estimated to be significantly over $42.3 billion Source links below.
Multiple myeloma - In preliminary studies, OWCP's in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100% malignant cell death in 60% of cases. This formulation will now be tested in a pre-clinical, IRB approved protocol on mice in an effort to duplicate those results.
Psoriasis - OWCP completed development of a Topical Cream infused with Cannabis oil extracts to be studied for Psoriasis skin disease. OWCP has finished the IRB (Institutional Review Board) protocol for Phase I equivalent, double blind, randomized and placebo-controlled study, which will be submitted for approval.
Post-Traumatic Stress Disorder ( PTSD ) - An estimated 8% of Americans - 24.4 million people - have PTSD at any given time. That is equal to the total population of Texas. At present,OWCP is negotiating with two other Israeli leading medical centers for the collaboration in the research of migraine and PTSD (post-traumatic stress disorder). The Company expects these agreements to be finalized during the fourth quarter of 2015.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.